# NEX-I

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nex-i

- Industry: Healthcare Specialists
- Headquarters: Seoul, South Korea
- Website: www.nex-i.co.kr/
- Total disclosed funding: $60M
- Latest round: Series B (Aug 12, 2025)
- Investors on record: 21

## About

Founded in 2021 and based in Seoul, South Korea, NEX-I, Inc., trading under the name NEX-I, is a bio venture and next-generation immunotherapy drug development company that specializes in immuno-cancer drugs that increase the response rate by discovering refractory inducing factors. The company is conducting research on drug administration to cancer patients who do not respond to immunotherapy with the goal to overcome the limitation of the low response rate of existing immunotherapy. In May 2026, NEX-I, Inc. raised KRW 50 billion in pre-IPO funding from new investors Korea Development Bank, DS Asset Management, and InterVest. Returning investors DSC Investment, Atinum Investment, T.S. Investment, WONIK Investment Partners, Hana Ventures, K2 Investment Partners, KB Investment, AJU IB Investment, QUAD Investment Management, Company K Partners, and Korea Investment & Securities also participated in the round.

NEX-I, Inc.  offers immuno-cancer drugs.

The company will use the May 2026 funding to support global clinical development and expand next-generation antibody-drug conjugate research.

## Funding rounds

- Series B, Aug 12, 2025, $44M — AJU IB Investment, KB Investment, Atinum Investment, Industrial Bank of Korea, Yuanta Investment, DSC Investment, WONIK Investment Partners, Company K Partners, CJ Investment, Korea Investment & Securities, QUAD Investment Management, T.S. Investment, K2 Investment Partners, Schmidt, Medytox Venture Investment, Stonebridge Ventures, Horizon Investment, Hana Ventures
- Series A, Oct 11, 2022, $16M — Atinum Investment, DSC Investment, WONIK Investment Partners, T.S. Investment, CJ ENM, Hana Ventures, Schmidt, Medytox Venture Investment, Green Cross Holdings, Stonebridge Ventures
- Seed, Jul 31, 2021 — Korea Tech Incubator for Startup, Schmidt

## Investors

- Korea Tech Incubator for Startup — Seed
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Seed, Series A, Series B
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A, Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A, Series B
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series A, Series B
- CJ ENM — Series A
- Hana Ventures — Series A, Series B
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A, Series B
- Green Cross Holdings — Series A
- Stonebridge Ventures — Series A, Series B
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Industrial Bank of Korea — Series B
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series B
- CJ Investment (https://capitalatlas.ai/funds/cj-investment) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series B
- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series B
- Horizon Investment (https://capitalatlas.ai/funds/horizon-investment) — Series B